Operative and Conservative Treatment of Uterine Sarcomas

 

 Permissions and Reprints

Abstract

Uterine sarcomas are rare, aggressive mesenchymal tumours with a relatively poor prognosis. The term comprises various histological subtypes, such as leiomyosarcoma, endometrial stromal sarcomas as well as undifferentiated uterine sarcomas, which require different operative and systemic/radiation therapy strategies accordingly. The evidence on operative, adjuvant and palliative treatment currently available is presented here.

Zusammenfassung

Uterussarkome sind seltene, aggressive mesenchymale Tumoren mit relativ schlechter Prognose. Sie umfassen diverse histologische Subtypen, etwa Leiomyosarkome, endometriale Stromasarkome sowie undifferenzierte uterine Sarkome, die entsprechend unterschiedliche operative und system- bzw. strahlentherapeutische Strategien erfordern. Die gegenwärtig verfügbare Evidenz zur operativen, adjuvanten und palliativen Therapie wird dargestellt.

• References

• 1 DʼAngelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116: 131-139
  CrossrefPubMedGoogle Scholar
• 2 Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76: 399-402
  PubMedGoogle Scholar
• 3 Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366: 491-505
  CrossrefPubMedGoogle Scholar
• 4 Leibsohn S, dʼAblaing G, Mishell jr. DR et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162: 968-974 discussion 974–966
  CrossrefPubMedGoogle Scholar
• 5 Gadducci A, Cosio S, Romanini A et al. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 2008; 65: 129-142
  CrossrefPubMedGoogle Scholar
• 6 Ramondetta L, Bodurka D, Deavers M et al. Uterine Sarcomas. In: Eifel PJ, Gershenson DM, Kavanagh JJ, Silva EG, eds. MD Anderson Cancer Care Series, Gynecologic Cancer. New York: Springer; 2006: 125-147
  Google Scholar
• 7 Park JY, Park SK, Kim DY et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011; 122: 255-259
  CrossrefPubMedGoogle Scholar
• 8 Reed NS, Mangioni C, Malmstrom H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818
  CrossrefPubMedGoogle Scholar
• 9 Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-581
  CrossrefPubMedGoogle Scholar
• 10 Pautier P, Floquet A, Gladieff L et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 2013; 24: 1099-1104
  CrossrefPubMedGoogle Scholar
• 11 Hensley ML, Wathen JK, Maki RG et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119: 1555-1561
  CrossrefPubMedGoogle Scholar
• 12 Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755-2763
  CrossrefPubMedGoogle Scholar
• 13 Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196
  CrossrefPubMedGoogle Scholar
• 14 van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886
  CrossrefPubMedGoogle Scholar
• 15 Chawla SP, Blay JY, Ray-Coquard I et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol, ASCO Annual Meeting Abstracts 2011; 29 (Suppl.) Abstract 10005
  PubMedGoogle Scholar
• 16 Schöffski P, Ray-Coquard IL, Cioffi A et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12: 1045-1052
  CrossrefPubMedGoogle Scholar
• 17 Harter P, Canzler U, Lueck H et al. Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: a phase II trial of the AGO study group. J Clin Oncol, ASCO Annual Meeting Abstracts 2011; 29 (Suppl.) Abstract 5093
  PubMedGoogle Scholar
• 18 Garcia-Del-Muro X, Lopez-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528-2533
  CrossrefPubMedGoogle Scholar
• 19 Pautier P, Floquet A, Cupissol D et al. LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): first results in patients with u-LMS. J Clin Oncol 2013; 31 (Suppl.) Abstract 10505
  PubMedGoogle Scholar
• 20 Tavassoli FA, Devilee P. WHO classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003
  CrossrefGoogle Scholar
• 21 Ashraf-Ganjoei T, Behtash N, Shariat M et al. Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol 2006; 4: 50
  CrossrefPubMedGoogle Scholar
• 22 Jin Y, Pan L, Wang X et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer 2010; 20: 1535-1539
  PubMedGoogle Scholar
• 23 Leath 3rd CA, Huh WK, Hyde jr. J et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007; 105: 630-634
  CrossrefPubMedGoogle Scholar
• 24 Li AJ, Giuntoli 2nd RL, Drake R et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 2005; 106: 1304-1308
  CrossrefPubMedGoogle Scholar
• 25 Chan JK, Kawar NM, Shin JY et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210-1215
  CrossrefPubMedGoogle Scholar
• 26 Pink D, Lindner T, Mrozek A et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101: 464-469
  CrossrefPubMedGoogle Scholar
• 27 Cheng X, Yang G, Schmeler KM et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 2011; 121: 323-327
  CrossrefPubMedGoogle Scholar
• 28 Beck TL, Singhal PK, Ehrenberg HM et al. Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecol Oncol 2012; 125: 141-144
  CrossrefPubMedGoogle Scholar
• 29 Berchuck A, Rubin SC, Hoskins WJ et al. Treatment of endometrial stromal tumors. Gynecol Oncol 1990; 36: 60-65
  CrossrefPubMedGoogle Scholar
• 30 Gadducci A, Landoni F, Sartori E et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996; 62: 25-32
  CrossrefPubMedGoogle Scholar

• Supplementary Material